Journal of NeuroInterventional Surgery · 2025 · 11 citations · 10 references
MedicineNeurosurgerySurgeryCerebrovascular NeurosurgeryCerebrovascular SurgeryVascular SurgeryAneurysm RepairAneurysm SurgeryCerebrovascular DiseaseStrokeStroke SurgerySubarachnoid Hemorrhage ManagementAcute Ischemic Stroke InterventionAcute Ischemic Stroke TreatmentAneurysm RetreatmentAneurysm Sac OcclusionAngiographic SuccessClinical Trial Efficacy EndpointsNeurovascular Device DesignNeurovascular Device Evaluation
BACKGROUND: Intrasaccular devices have broadened treatment options for wide necked aneurysms. This study presents the preliminary experience with the Artisse 2.0 device. METHODS: Innovative NeurovaScular Product SurveIllance REgistry (INSPIRE) is a non-randomized, multicenter, real world clinical study with treatment arms for aneurysms (INSPIRE-A) and acute ischemic stroke (INSPIRE-S). This interim analysis included 87 patients enrolled from November 2022 to April 2024 in the INSPIRE-A Artisse cohort across 16 Europoean centers. Procedures followed standard clinical care, with 6 months of follow-up. Safety and efficacy endpoints included major stroke, neurological death, serious adverse events (SAEs), aneurysm occlusion, and retreatment rates. An independent core laboratory assessed imaging, and all SAEs were reviewed by a clinical events committee. The Artisse steering committee provided independent oversight of the data. RESULTS: The Artisse device achieved an overall successful implantation rate of 96.6% (84/87), with satisfactory placement rates of 98.7% (74/75) for unruptured and 88.9% (8/9) for ruptured aneurysms. Following the procedure, 46.2% of unruptured aneurysm patients were receiving antiplatelet therapy (APT), predominantly aspirin monotherapy, while no ruptured aneurysm patients received APT. Device related SAE rate was 1.3% (1/87), and the overall stroke rate was 2.3% (2/87), including both ruptured and unruptured aneurysms. At 6 months, 80.0% (28/35) of patients with unruptured aneurysms showed complete obliteration, with no recurrences or retreatments. CONCLUSIONS: Preliminary experience with the Artisse 2.0 device demonstrated high technical success, favorable safety, and efficacy in aneurysm obliteration at 6 months. Larger studies with longer follow-up periods are needed to confirm these findings.
10
Adam S Arthur, Andy Molyneux, Alexander L. Coon et al. · Journal of NeuroInterventional Surgery · 2019 · 335 citations · Full text
Medicine, Neurosurgery, Surgery +11
The Woven EndoBridge: A New Aneurysm Occlusion Device
Yumei Ding, Debra A. Lewis, Ramanathan Kadirvel et al. · American Journal of Neuroradiology · 2011 · 168 citations · Full text
Medicine, Neurosurgery, Surgery +12